Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorpromazine with Standard of Care in Newly Diagnosed Glioblastoma
NCT05190315Phase 1Completed
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Aminazin in glioblastoma multiforme (GBM). Primary endpoints: Safety and acute toxicity of chlorpromazine and Recommended phase II dose of chlorpromazine at 4 weeks. Started Jan 2022; status: completed.
02
Drugs
Aminazin
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05190315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190315.